BACKGROUND: Randomized controlled trials (RCTs) of duloxetine (DLX), an inhibitor of both norepinephrine and serotonin transporters (SNRI), have tested its efficacy in acute major depressive disorder (MDD) versus placebo (PBO) or standard serotonin-reuptake inhibitors (SRIs) and require review, comparing analytical methods. METHOD: Computerized searching to identify reports of RCTs of DLX in adult, acute MDD patients permitted meta-analytic pooling to estimate overall response and remission rates, to compare mixed-model, repeated measures (MMRM) versus last-observations-carried-forward (LOCF) analytical methods, and to assess relations of DLX dose to efficacy and adverse outcomes. RESULTS: We identified 17 RCTs involving 22 comparisons (DLX...
The aim of the present paper was to compare the efficacy and safety of duloxetine with paroxetine in...
Oft-cited trial-level meta-analyses casting doubt on the usefulness of antidepressants have been bas...
Duloxetine (DLX) is a dual serotonin and norepinephrine reuptake inhibitor that has been recently ap...
BACKGROUND: Randomized controlled trials (RCTs) of duloxetine (DLX), an inhibitor of both norepineph...
BACKGROUND: Although pharmacological and psychological interventions are both effective for major de...
BACKGROUND: Duloxetine is a balanced and potent dual reuptake inhibitor of serotonin (5-HT) and nore...
BACKGROUND: Data comparing duloxetine with existing antidepressant treatments is limited. A comparis...
Benchalak Maneeton,1 Narong Maneeton,1 Surinporn Likhitsathian,1 Pakapan Woottiluk,2 Punjaree Wiriya...
Abstract Background Major depression significantly impairs quality of life, increases the risk of su...
Management of depression presents a significant medical challenge. Drugs with improved efficacy and ...
BACKGROUND: Major depressive disorders (MDD) present a significant public health problem, in terms o...
Objective: Major depressive disorder (MDD) is a significant public health concern and challenges hea...
Background: Data comparing duloxetine with existing antidepressant treatments is limited. A comparis...
Although pharmacological and psychological interventions are both effective for major depression, an...
A developing concept is that antidepressant strategies which combine multiple mechanisms of action m...
The aim of the present paper was to compare the efficacy and safety of duloxetine with paroxetine in...
Oft-cited trial-level meta-analyses casting doubt on the usefulness of antidepressants have been bas...
Duloxetine (DLX) is a dual serotonin and norepinephrine reuptake inhibitor that has been recently ap...
BACKGROUND: Randomized controlled trials (RCTs) of duloxetine (DLX), an inhibitor of both norepineph...
BACKGROUND: Although pharmacological and psychological interventions are both effective for major de...
BACKGROUND: Duloxetine is a balanced and potent dual reuptake inhibitor of serotonin (5-HT) and nore...
BACKGROUND: Data comparing duloxetine with existing antidepressant treatments is limited. A comparis...
Benchalak Maneeton,1 Narong Maneeton,1 Surinporn Likhitsathian,1 Pakapan Woottiluk,2 Punjaree Wiriya...
Abstract Background Major depression significantly impairs quality of life, increases the risk of su...
Management of depression presents a significant medical challenge. Drugs with improved efficacy and ...
BACKGROUND: Major depressive disorders (MDD) present a significant public health problem, in terms o...
Objective: Major depressive disorder (MDD) is a significant public health concern and challenges hea...
Background: Data comparing duloxetine with existing antidepressant treatments is limited. A comparis...
Although pharmacological and psychological interventions are both effective for major depression, an...
A developing concept is that antidepressant strategies which combine multiple mechanisms of action m...
The aim of the present paper was to compare the efficacy and safety of duloxetine with paroxetine in...
Oft-cited trial-level meta-analyses casting doubt on the usefulness of antidepressants have been bas...
Duloxetine (DLX) is a dual serotonin and norepinephrine reuptake inhibitor that has been recently ap...